Full-year guidance was left unchanged as ACA policy uncertainty and GLP-1 drugs were cited as pressures on surgical volume.
Intuitive Surgical fell as much as 13% in after-hours trading after da Vinci procedure growth slowed to a four-year low. The company left its full-year guidance unchanged, even as the update pointed to ACA (Affordable Care Act) policy uncertainty and GLP-1 drugs (weight-loss and diabetes medicines) as factors weighing on surgical volume. The move suggests investors were focused on softer procedure momentum and on whether healthcare policy and changing patient treatment patterns could continue to pressure demand.